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Aims: To evaluate in detail the extent to which step sectioning and immunohistochemical examination of
sentinel lymph nodes (SLNs) in patients with melanoma reveal additional node positive patients, to arrive
at a sensitive yet workable protocol for histopathological SLN examination.
Methods: The study comprised 29 patients with one or more positive SLN after a successful SLN procedure
for clinical stage I/II melanoma. SLNs were lamellated into pieces of approximately 0.5 cm in size. One
initial haematoxylin and eosin (H&E) stained central cross section was made for each block. When
negative, four step ribbons were cut at intervals of 250 mm. One section from each ribbon was stained
with H&E, and one was used for immunohistochemistry (IHC).
Results:When taking the cumulative total of detected metastases at level 5 as 100%, the percentage of SLN
positive patients increased from 79%, 83%, 83%, 90% to 93% in the H&E sections through levels 1–5, and
with IHC these values were 83%, 86%, 90%, 97%, and 100%, respectively. One of six patients in whom
metastases were detected at levels 2–5 only had metastases in the subsequent additional lymph node
dissection.
Conclusions: Multiple level sectioning of SLNs (five levels at 250 mm intervals) and the use of IHC detects
additional metastases up to the last level in melanoma SLNs. Although more levels of sectioning might
increase the yield even further, this protocol ensures a reasonable workload for the pathologist with an
acceptable sensitivity when compared with the published literature.
S
ince the early 1990s a simple method has been available
to detect and retrieve the first tumour draining lymph
node, the so called sentinel lymph node (SLN). This is
done with a radioactive tracer and blue dye, which are both
injected around the tumour.1–3 During surgery, guided by the
blue staining of the draining tissues, the radioactivity, and
the preoperatively made lymphoscintigraphy, the SLN is
removed and examined meticulously by the pathologist.
When the SLN is identified successfully, the absence of
tumour in this node predicts with a high degree of accuracy
the absence of metastases in the remaining additional lymph
nodes.4–7 The concept of the SLN as the first lymph node that
drains a primary tumour has been validated extensively in
the past few years. The SLN procedure had become the
standard procedure for melanoma in many centres.
‘‘A compromise must be found between workload and
sensitivity by limiting the degree of step sectioning and
immunohistochemistry on multiple levels’’
The reliability of the SLN procedure as an accurate staging
procedure is dependent on the ability to identify the true SLN
and the extent of histopathological examination of the SLN.
Both are instrumental in limiting the false negative rate of the
SLN procedure. Most metastatic deposits are thought to be
found along the midplane of the node; therefore bisecting the
node through the hilar plane, as recently described by Roberts
and Cochran, may optimise the finding of metastases.8
Multiple level sectioning has been shown to increase the
detection rate of SLN metastases in several studies.9 10 How-
ever, complete serial sectioning would result in an unaccep-
table workload for the pathologist. Therefore, a compromise
must be found between workload and sensitivity by limiting
the degree of step sectioning and immunohistochemistry
(IHC) on multiple levels. To date, no consensus exists on the
most (cost)effective protocol for pathological analysis of
SLNs. In fact, only a few studies have reported on the precise
yield of each additional level of step sectioning and
immunohistochemistry in breast8 and vulvar cancer,10 but
no such study has yet been published for melanoma.
The traditional protocol used in our hospital includes step
sectioning at 250 mm, as for other cancers. Although this
protocol has yielded good clinical results for melanoma, it is
not strictly evidence based, but rather experience based.
Therefore, our study was performed to evaluate in detail the
yield of multiple levels and the use of IHC for detecting
metastases in SLNs, to arrive at an evidence based protocol
for optimal SLN investigation.
MATERIAL AND METHODS
From a total of 189 consecutive patients with clinical stage
I/II melanoma who underwent a successful SLN procedure
from to January 1998 to September 2002, we identified 29
patients in whom one or more SLN proved to be positive. The
mean age of the patients was 52 years (range, 35–79), and
the mean Breslow thickness was 2.78 mm (range, 0.69–12).
We evaluated the extent of SLN processing required before
these patients were found to be positive. All patients who
were initially negative by haematoxylin and eosin (H&E) on
the first SLN section subsequently underwent standard
multiple sectioning at 250 mm intervals and staining with
Abbreviations: H&E, haematoxylin and eosin; IHC,
immunohistochemistry; SLN, sentinel lymph node
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both H&E and IHC. We assessed at which additional level
patients who were initially found to be negative were
subsequently converted to being SLN positive.
Sentinel node biopsy
The day before surgery, 40 MBq of 99mTc colloidal albumin
was injected in two to four depots peritumorally. Lympho-
scintigraphy was done to detect the presence, location, and
number of focal accumulations.
Just before surgery, 0.5 ml of 2.5% patent blue solution
(Guerbet, Aulnay-sous Bois, France) was injected intracuta-
neously just around the scar on the site of the primary
tumour or, when the tumour was still in situ, around the
tumour. During surgery, focal tracer accumulations were
localised using a handheld c probe (c-track; Carewise,
Morgan Hill, California, USA). All hot and blue nodes were
removed as SLNs. Furthermore, all radioactive nodes were
biopsied until less than 10% of residual radioactivity,
compared with the activity of the hottest SLN, remained in
the lymph node basin. All patients underwent regional lymph
node dissection after a positive SLN was detected.
Tissue processing
SLNs smaller than 0.5 cm were processed intact, those
between 0.5 and 1 cm were halved, and SLNs larger than
1 cm were lamellated into pieces of approximately 0.5 cm in
size. They were fixed in neutral buffered formaldehyde and
embedded completely. One initial 4 mm thick H&E stained
section was made from each block. When negative, an
additional section was done at the first level for IHC and four
step ribbons were cut at an interval of 250 mm. From these
ribbons one section was stained with H&E, one was used
for IHC with S100, and one for HMB45 or Melan-A IHC
(Dako A/D, Glostrup, Denmark). All slides were examined by
the same pathologist (PJvD). All SLNs containing any cell
compatible with melanoma cell morphology (and immuno-
phenotype) were considered metastasis positive.
RESULTS
Of the 29 patients eventually found to have positive SLNs, 23
were positive on the first SLN section stained with H&E. Inte-
restingly, both patients with more than one positive SLN were
found to have SLN metastases on the first H&E stained section.
With additional step sectioning and IHC in the remaining
six patients, the percentage of SLN positive patients increased
from 79%, 83%, 83%, 90%, to 93% in the H&E sections through
levels 1–5. With IHC these figures were 83%, 86%, 90%, 97%,
and 100%, respectively. At the first level, IHC revealed one
additional SLN positive patient and the additional levels 2–5
revealed metastases in one, one, two, and one more patient,
respectively (table 1). Of the six patients with SLN metastases
only detected at levels 2–5, one had further metastases in the
subsequent additional lymph node dissection.
Looking at all harvested nodes in these 29 SLN positive
patients, 31 tumour positive SLNs were found. When taking
the cumulative total of detected metastases at level 5 as
100%, the percentage of positive SLNs increased from 81%,
84%, 84%, 90%, to 94% in the H&E sections through levels
1–5. With IHC, the increase was from 84%, 87%, 90%, 97%, to
100%, respectively. The first level failed to detect metastases
in five SLNs. Additional levels 2–5 yielded metastases in one,
one, two, and one more positive SLN, respectively (table 2).
DISCUSSION
Because validation studies have shown high accuracy rates
for the SLN procedure,11 it can now be used as a staging
procedure without the need for completion lymph node
dissection in patients with negative SLNs.4 5 11 12
As long as the surgeon has performed a reliable SLN biopsy
procedure, it is up to the pathologist to determine whether
lymph node metastases are present or not.
In the days of routine elective lymph node dissection, it
was shown that a large proportion of patients are converted
from node negative to node positive with a more detailed
histological examination of lymph nodes.13 14 This has
important consequences for the clinical management of
these patients because, in general, lymph node positive
patients will have a worse prognosis.2 For these reasons, the
histopathological examination of SLNs tends to be even more
elaborate, with the additional argument that this can be done
with an acceptable workload for the pathologist because only
a few nodes need to be examined this way.
Our study clearly shows that more patients are converted
to node positive with each additional step of sectioning (at
250 mm intervals), and that with each additional step IHC
has a higher sensitivity than H&E.
However, even with this intensive protocol not all nodal
metastases will be detected. Such a 100% sensitivity can
theoretically only be reached with complete serial sectioning
of the SLN at 12 mm intervals.10 In the study of Cook et al,
reverse transcription polymerase chain reaction analysis
slightly increased sensitivity for the detection of metastases,
but at the cost of false positivity.14 Therefore, the place of this
technique in routine diagnosis remains to be established.
However, the question arises whether all metastatic cells
need to be found. From a clinical point of view, only SLN
metastases that are accompanied by second echelon or
distant metastases need to be identified. Therefore, a method
that has a sufficiently high clinical sensitivity with an
acceptable workload for the pathologist needs to be defined.
Complete step sectioning of the SLN in patients with breast
cancer has been done in only a few studies. For instance,
Cserni serially sectioned the SLN up to extinction with 3–5 mm
thick slices and examined every 10–20th level.15 In the final
analysis, 15 of the 21 patients with metastases limited to the
SLN were positive on the initial central cross section.
Dowlatshahi et al performed complete serial sectioning at
250 mm intervals and found that only six of 30 SLN positive
patients were positive on the initial section examined by H&E
and IHC.16 This difference is remarkable, also in view of the
Table 1 Cumulative number of patients with melanoma
sentinel node metastases found with haematoxylin & eosin
(H&E) and immunohistochemistry (IHC) in each additional
level (250 mm intervals) in 29 patients
H&E % IHC %
Level 1 23 79 24 83
Level 2 24 83 25 86
Level 3 24 83 26 90
Level 4 26 90 28 97
Level 5 27 93 29 100
Table 2 Cumulative number of metastases found with
haematoxylin & eosin (H&E) and immunohistochemistry
(IHC) in each additional level (250 mm intervals) in 31
cutaneous melanoma sentinel nodes
H&E % IHC %
Level 1 25 81 26 84
Level 2 26 84 27 87
Level 3 26 84 28 90
Level 4 28 90 30 97
Level 5 29 94 31 100
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fact that Cserni’s intervals were smaller and therefore it would
be expected that a greater number of additional metastases
would be found. The greater yield on the initial section in
Cserni’s study could be ascribed to the fact that they tried to
cut the central cross section guided by the blue lymphatic
vessel, which we did not, or the different biological properties
of breast cancer and melanoma cells. In addition, the average
size of the metastases may have been greater in patients in
Cserni’s study (68% T2 tumours compared with 25% in the
study by Dowlatshahi et al). No studies of complete sectioning
of the SLN in patients with melanoma have been published,
but the same results would be expected in melanoma.
‘‘Immunohistochemistry facilitates the detection of single
metastatic cells, and speeds up the screening of the
sections dramatically’’
Nevertheless, the fact remains that the use of IHC and
additional step sectioning improves the detection rate of
metastatic deposits. The question for practical purposes then
remains: how many additional levels (and at what interval)
need to be examined?
Turner et al examined 10 levels at 40 mm intervals in 42
patients with SLN positive breast cancer in whom the initial
H&E section was negative.17 With the use of IHC, the first two
levels of SLN examination found additional metastases in all
but one of these patients. Therefore, they concluded that the
additional eight levels of examination did not significantly
contribute to the detection of additional metastases. However,
with 10 levels at 40 mm intervals, only 400 mm of the entire
SLN slice (up to 5000 mm in thickness) is examined, which is
unlikely to be sufficient for the detection of all metastases.
Rather than taking many sections at small intervals, it may be
more efficient to take fewer sections at larger step intervals.
Cook et al showed that in different patient groups, the
percentage of SLN positive patients with IHC protocols
involving only bivalving through the hilar plane, two
additional levels with 50 mm interval, and four additional
levels at 50 mm were 17.8%, 25.2%, and 33.8%, respectively.
However, no direct evaluation of the contribution of each
additional level was provided.
Our present study shows in detail the yield of step section-
ing and IHC at five levels with an interval of 250 mm. In prac-
tice, this has proved to be an acceptable workload. Clearly, the
yield increased with additional levels. The first level failed to
detect metastases in five SLNs (16% of the total number of
metastases found). Additional levels 2–5 yielded metastases
in one, one, two, and one more SLN, respectively. Thus, addi-
tional levels clearly reveal more metastases and even the
fourth and fifth level together reveal 10% additional metas-
tases. Not surprisingly, the yield with IHC was higher than
with H&E only. IHC facilitates the detection of single metas-
tatic cells, and speeds up the screening of the sections drama-
tically. Therefore, some investigators omit H&E staining when
IHC is performed. However, we prefer to make H&E control
sections because they are helpful in the detection of artefacts
and benign inclusions.
These results are comparable to the number of additional
metastases found by Torrenga et al in the SLNs of patients
with breast cancer.9 They studied SLNs of patients with breast
cancer processed in our institute according to the same
protocol.
In conclusion, step sectioning of SLNs with IHC is very
useful for finding the smallest metastases in SLNs of breast
cancer that may be clinically relevant. Therefore, we propose
step sectioning and IHC at four additional levels, separated by
250 mm intervals, when the original H&E section is tumour
negative. Despite the fact that our protocol might still miss
some metastases we believe that this protocol ensures a
reasonable workload for the pathologist with an acceptable
sensitivity.
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Take home messages
N To optimise the detection of metastases in patients with
melanoma, we propose step sectioning of sentinel
lymph nodes and immunohistochemistry at four addi-
tional levels, separated by 250 mm intervals, when the
original haematoxylin and eosin section is tumour
negative
N Although more levels of sectioning might increase the
yield even further, this protocol ensures a reasonable
workload for the pathologist with an acceptable
sensitivity
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